• Users Online: 128
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2022| July-September  | Volume 1 | Issue 3  
    Online since September 30, 2022

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
EDITORIAL
Cardiovascular diseases guideline-directed medical therapy in low- and middle-income countries: A call for action
Hisham A Badreldin, Suliman Alghnam
July-September 2022, 1(3):67-68
DOI:10.4103/sjcp.sjcp_17_22  
  664 203 -
ORIGINAL ARTICLE
Efficacy and predictors to response of octreotide and midodrine combination in patients with hepatorenal syndrome
Zinah Alabdulkarim, Dalal Alkortas, Mohammed Ibrahim Alsebayel, Faisal Aba Alkhail, Hussien Elsiesy, Ahmed Al-Jedai
July-September 2022, 1(3):69-74
DOI:10.4103/sjcp.sjcp_4_22  
Background: Hepatorenal syndrome (HRS) is a functional form of acute kidney injury (AKI) that develops in patients with advanced liver disease. The use of octreotide (OCT) and midodrine (MID) along with albumin is commonly used in practice despite lack of strong evidence. Objective: The purpose of the study is to evaluate the efficacy of combining octreotide and midodrine in HRS patients. Materials and Methods: This is a retrospective, single center study. All patients who received both OCT/MID from January 2005 to April 2013 were identified from the electronic pharmacy system at a major tertiary care center in Riyadh, Saudi Arabia. The aim of the study is to evaluate the safety and efficacy and predictors to response of the combination of OCT/MID in patients with decompensated liver cirrhosis with type I HRS receiving standard of care therapy. The primary endpoint was the change in estimated glomerular filtration rate (eGFR) within 30 days of starting therapy compared to baseline. Results: There was no significant improvement in eGFR using Cockcroft-Gault (CG) from baseline until the end of treatment (P = 0.311). Conclusion: Combination therapy of octreotide and midodrine along with albumin did not improve the eGFR in patients with type 1 HRS.
  741 106 -
ABSTRACTS
The 2nd International Annual Conference of the SSCP Accepted Abstract: Clinical Pharmacy; Healthcare Professionals Theme

July-September 2022, 1(3):79-87
DOI:10.4103/WKMP-0249.357710  
  718 108 -
The 2nd International Annual Conference of the SSCP Accepted Abstract: Clinical Pharmacy; Students Theme

July-September 2022, 1(3):87-96
DOI:10.4103/WKMP-0249.357711  
  706 76 -
CASE REPORT
Clinical course of a case of elizabethkingia meningoseptica in a critical neonate at a tertiary care hospital in Saudi Arabia
Faisal Aqeel AlSehli, Nawaf Sami Alsaeed, AlAnoud TofailAhmed Rajah, Saif AlSaif
July-September 2022, 1(3):75-78
DOI:10.4103/sjcp.sjcp_11_22  
Case Report: In this paper we discuss the clinical course of a 25-week gestational age preterm neonate who suffered with multiple comorbidities atop of an E. meningoseptica infection causing meningitis and hydrocephalus. A multitude of antibiotics were administered to the child, such as vancomycin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifampicin. However, the pathogen either had prior resistance to the agents or newly developed resistance along the disease course. After many trials of antibiotics, the usage of ceftazidime/avibactam and moxifloxacin dual therapy induced clinical and microbiological eradication of the pathogen. Objective: This case report aims to discuss the multidrug approach used to treat a preterm neonates Elizabethkingia Meningoseptica infection in a Tertiary Care Hospital in Saudi Arabia. Conclusion: E. meningoseptica is an uncommon infectious agent which can cause meningitis and even sepsis that is difficult to treat due to its multidrug resistance phenotype. Continuous reviews of new case reports on successful attempts of treating E. meningoseptica are paramount to maintaining updated therapy options for newly encountered cases in day-to-day practice in the neonatal intensive care unit (NICU).
  550 83 -
ABSTRACTS
The 2nd International Annual Conference of the SSCP Accepted Abstract: Pharmacotherapy; Healthcare Professionals

July-September 2022, 1(3):96-102
DOI:10.4103/WKMP-0249.357712  
  479 79 -
The 2nd International Annual Conference of the SSCP Accepted Abstract: Pharmacotherapy; Students Theme

July-September 2022, 1(3):102-104
DOI:10.4103/WKMP-0249.357713  
  484 67 -